Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 28;10:15886. doi: 10.1038/s41598-020-72878-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

CSF sTREM2 within clinical presentation groups and AT categories. (A) Cerebrospinal fluid (CSF) sTREM2 levels did not relate to the AD clinical presentation. There was no difference in the CSF sTREM2 levels when comparing the cognitively unimpaired with patients having a clinical presentation of mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) (p = 0.31, Kruskal–Wallis test, n = 113, n = 62, n = 237, respectively). (B) CSF sTREM2 related to AT status. When all individuals included were stratified according to the AT classification CSF sTREM2 was higher among those with biomarker data suggestive of tau pathology (T) *p < 0.001 obtained by Mann–Whitney-test. (C) The stratification according to the AT system within the clinical groups also showed higher CSF sTREM2 among those with biomarker data suggestive of tau pathology (AD-MCI **p = 0.02, AD dementia * and cognitively unimpaired *p < 0.001, p values obtained by Kruskal–Wallis test). Data are presented with individual values with smaller and larger lines representing the mean and standard deviation, respectively.